WAVE Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings data on Wednesday. The company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.14, Bloomberg Earnings reports. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.73 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%.

WAVE Life Sciences (NASDAQ WVE) remained flat at $18.10 during mid-day trading on Thursday. 71,449 shares of the stock were exchanged. The company’s 50-day moving average is $18.92 and its 200-day moving average is $23.27. The company’s market capitalization is $501.68 million. WAVE Life Sciences has a one year low of $15.15 and a one year high of $40.15.

In other news, insider Michael A. Panzara sold 7,414 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total value of $123,591.38. Following the completion of the transaction, the insider now owns 15,336 shares of the company’s stock, valued at $255,651.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 53.00% of the company’s stock.

A number of research firms have commented on WVE. Zacks Investment Research downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Jefferies Group LLC set a $42.00 price objective on shares of WAVE Life Sciences and gave the company a “buy” rating in a report on Thursday, June 8th. ValuEngine downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Finally, JMP Securities reiterated an “outperform” rating and issued a $40.00 price objective on shares of WAVE Life Sciences in a report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.00.

ILLEGAL ACTIVITY NOTICE: “WAVE Life Sciences Ltd. (WVE) Announces Earnings Results” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/10/wave-life-sciences-ltd-wve-announces-earnings-results.html.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Earnings History for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.